Rapid identification of Candida glabrata in Candida bloodstream infections

Journal of Medical Microbiology

Volumn 56, Issue 12, 2007, Pages 1639-1643

  Foster, Nicholas ^a   Symes, Charlotte ^a   Barton, Richard ^a   Hobson, Richard ^a  

^a Old Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; BLOOD CULTURE; BLOOD FLOW; CANDIDA GLABRATA; CANDIDIASIS; CLINICAL OBSERVATION; DEVICE; FUNGAL DETECTION; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; INCUBATION TIME; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL;

ANAEROBIOSIS; BLOOD; CANDIDA GLABRATA; CANDIDIASIS; CULTURE MEDIA; FUNGEMIA; HUMANS; MICROBIOLOGICAL TECHNIQUES; RETROSPECTIVE STUDIES;

EID: 37249047494     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47406-0     Document Type: Article

References (17)

1. Clark, T. A. & Hajjeh, R. A. (2002). Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 15, 569-574.
2. Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A. & Pfaller, M. A. (2002). Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40, 1298-1302.
3. Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N. & Wenzel, R. P. (1999). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29, 239-244.
4. Fitzgibbons, N., Monahan, J. S., Fang, F. C. & Madinger, N. E. (2001). Rapid presumptive identification of Candida glabrata using BACTEC Lytic/10 Anaerobic/F Medium. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, 16-19 December. Abstract no. D-1393. Denver, CO: University of Colorado Health Science Center.
5. Hobson, R. P. (2003). The global epidemiology of invasive Candida infection - is the tide turning? J Hosp Infect 55, 159-168.
6. Hope, W., Morton, A. & Eisen, D. P. (2002). Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 50, 56-65.
7. Horvath, L. L., Hospenthal, D. R., Murray, C. K. & Dooley, D. P. (2003). Detection of simulated candidemia by the BACTEC 9240 system with Plus Aerobic/F and Anaerobic/F blood culture bottles. J Clin Microbiol 41, 4714-4717.
8. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Jonhson, E. M., Perry, J. D., Sullivan, D. J. & Wilson, J. A. (2003). Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54, 18-24.
9. Lee, S. C., Fung, C. P., Huang, J. S., Tsai, C. J., Chen, K. S., Chen, H. Y., Lee, N., See, L. C. & Shieh, W. B. (2000). Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 44, 2715-2718.
10. Lees, E. & Barton, R. C. (2003). The use of Niger seed agar to screen for Candida dubliniensis in a clinical microbiology laboratory. Diagn Microbiol Infect Dis 46, 13-17.
11. Maschmeyer, G. (2006). The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 27 (Suppl. 1), 3-6.
12. Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., Edwards, J. E. & Infectious Diseases Society of America (2004). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161-189.
13. Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. & Diekema, D. J. (2002). In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46, 1723-1727.
14. Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J. & Diekema, D. J. (2003). Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 41, 2176-2179.
15. Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G. & other authors (1997). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24, 235-247.
16. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P. & the National Nosocomial Infections Surveillance System Hospitals (2002). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35, 627-630.
17. Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. & Wenzel, R. P. (1988). Hospital acquired candidaemia. The attributable mortality and excess length of stay. Arch Intern Med 148, 2642-2645.